To appraise the clinical and cost effectiveness of DCVax-L for newly diagnosed glioblastoma multiforme.
 
Status In progress
Process STA pre-2018
ID number 836

Provisional Schedule

Committee meeting: 1 08 November 2018
Expected publication 01 May 2019

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Northwest Biotherapeutics (DCVax-L)
Others Department of Health and Social Care
  NHS Blackburn with Darwen CCG
  NHS England
  NHS Wyre Forest CCG
  Welsh Government
Patient carer groups Astro Brain Tumour Fund
  Black Health Agency
  Brain and Spine Foundation
  Brain Charity
  Brain Tumour Action
  Brain Tumour Charity
  Brainstrust
  British Brain Tumour Association
  Cancer 52
  Cancer Black Care
  Cancer Equality
  HAWC
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Assocation of Anaesthetists
  Association of British Neurologists
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Head and Neck Oncologists
  British Association of Head and Neck Oncology Nurses
  British Association of Surgical Oncology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Skull Base Society
  Cancer Research UK
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  Society of British Neurological Surgeons
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Andrew McCartney Trust Fund for Brain Tumour Research
  Brain Tumour Research
  Brain Tumour Research Campaign
  Institute of Cancer Research
  Institute of Neurology, UCL
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Oracle Cancer Trust

Timeline

Key events during the development of the guidance:

Date Update
14 June 2018 Invitation to participate
03 April 2018 - 01 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
16 August 2017 As you will be aware, the Department of Health has asked NICE to conduct an appraisal of DCVax-L for treating newly diagnosed glioblastoma Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-August 2018
26 January 2017 - 23 February 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance